C:\Program Files\Stnexp\Queries\10556932.str






```
chain nodes :
    13  15  16  17
ring nodes :
    1  2  3  4  5  6  7  8  9  10  18  19  20  21  22  23
ring/chain nodes :
    11
chain bonds :
    13-15  15-16  15-17  17-23
ring bonds :
    1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10  18-19  18-23  19-20  20-21  21-22
    22-23
exact/norm bonds :
    13-15  15-16  15-17  17-23
normalized bonds :
    1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10  18-19  18-23  19-20  20-21  21-22
    22-23
isolated ring systems :
    containing 1 : 18 :


Match level :
    1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom  11:CLASS
    12:Atom  13:CLASS  14:Atom  15:CLASS  16:CLASS  17:Atom  18:Atom  19:Atom  20:Atom  21:Atom
    22:Atom  23:Atom
Generic attributes :
    17:
    Saturation             : Unsaturated
    Number of Carbon Atoms : less than 7
    Number of Hetero Atoms : 2 or more
    Type of Ring System    : Monocyclic

Element Count :
    Node 17: Limited
        C,C4
        N,N2
```

O,OO
S,S0

=>
Uploading C:\Program Files\Stnexp\Queries\10556932.str



chain nodes :
13 15 16 17
ring nodes :
1 2 3 4 5 6 7 8 9 10 18 19 20 21 22 23
ring/chain nodes :
11
chain bonds :
13-15 15-16 15-17 17-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 18-19 18-23 19-20 20-21
21-22 22-23
exact/norm bonds :
13-15 15-16 15-17 17-23
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 18-19 18-23 19-20 20-21
21-22 22-23
isolated ring systems :
containing 1 : 18 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 13:CLASS 14:Atom 15:CLASS 16:CLASS 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom
Generic attributes :
17:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : 2 or more
Type of Ring System : Monocyclic

Element Count :
Node 17: Limited
C,C4
N,N2
O,O0
S,S0

```
L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 14:05:48 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    15663 TO ITERATE

 12.8% PROCESSED     2000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       305764 TO   320756
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 sss ful
FULL SEARCH INITIATED 14:06:01 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   314424 TO ITERATE

100.0% PROCESSED   314424 ITERATIONS                              15 ANSWERS
SEARCH TIME: 00.00.03

L3           15 SEA SSS FUL L1

=> => s l3
L4           1 L3

=> d l4 bib,ab,hitstr
```

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:1037093 CAPLUS
DN 142:23303
TI Preparation of pyrimidine derivatives having 2-aminoquinoline moiety as MCH receptor antagonists
IN Moriya, Minoru; Suzuki, Takao; Ishihara, Akane; Iwaasa, Hisashi; Kanatani, Akio
PA Banyu Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DT Patent
LA Japanese

Applicant's

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004103992	A1	20041202	WO 2004-JP7217	20040520
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004241213	A1	20041202	AU 2004-241213	20040520
	CA 2526374	A1	20041202	CA 2004-2526374	20040520
	EP 1630162	A1	20060301	EP 2004-734111	20040520
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	CN 1791594	A	20060621	CN 2004-80013778	20040520
	IN 2005DN04938	A	20071207	IN 2005-DN4938	20051027
	US 20060287340	A1	20061221	US 2005-556932	20051116
PRAI	JP 2003-143398	A	20030521		
	WO 2004-JP7217	W	20040520		

OS MARPAT 142:23303
AB Title compds. I [R1, R2 = alkyl, etc.; R3, R4, R6, R7 = H, alkyl, etc.; R5 = H, alkyl; R8 = halo, etc.; n = 0-4] were prepared For example, hydrogenation of nitro compound (R)-II followed by acylation with 5-phenylpyrimidine-2-carboxylic acid afforded compound (R)-III. In MCH (melanin concentrating hormone) binding assays, the IC50 value of compound (R)-III was 4.1 nM. Compds. I are claimed useful for the treatment of obesity, diabetes, etc.
IT 801252-02-8P 801252-05-1P 801252-08-4P
801252-11-9P 801252-14-2P 801252-17-5P
801252-21-1P 801252-26-6P 801252-31-3P
801252-34-6P 801252-37-9P 801252-40-4P
801252-43-7P 801252-46-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidine derivs. having 2-aminoquinoline moiety as MCH receptor antagonists for treatment of obesity, diabetes, etc.)
RN 801252-02-8 CAPLUS

CN 2-Pyrimidinecarboxamide, 5-(4-fluorophenyl)-N-[2-(1-methyl-2-oxo-1,7-diazaspiro[4.4]non-7-yl)-6-quinolinyl]- (CA INDEX NAME)



RN 801252-05-1 CAPLUS
CN 2-Pyrimidinecarboxamide, 5-(4-fluorophenyl)-N-[2-(2-methyl-3-oxo-2,7-diazaspiro[4.4]non-7-yl)-6-quinolinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 801252-08-4 CAPLUS
CN 2-Pyrimidinecarboxamide, N-[2-[(3R)-3-[methyl(2-methyl-1-oxopropyl)amino]-1-pyrrolidinyl]-6-quinolinyl]-5-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 801252-11-9 CAPLUS
CN 2-Pyrimidinecarboxamide, N-[2-(6-acetyloctahydropyrrolo[3,4-d]azepin-2(1H)-yl)-6-quinolinyl]-5-phenyl- (CA INDEX NAME)



RN 801252-14-2 CAPLUS
CN 2-Pyrimidinecarboxamide, N-[2-[(3R)-3-(acetylmethylamino)-1-pyrrolidinyl]-6-quinolinyl]-5-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 801252-17-5 CAPLUS
CN 2-Pyrimidinecarboxamide, N-[2-[(3R)-3-[methyl(1-oxopropyl)amino]-1-pyrrolidinyl]-6-quinolinyl]-5-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 801252-21-1 CAPLUS
CN 2-Pyrimidinecarboxamide, N-[2-[(3R)-3-[methyl(methylsulfonyl)amino]-1-pyrrolidinyl]-6-quinolinyl]-5-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 801252-26-6 CAPLUS
CN Carbamic acid, methyl[(3R)-1-[6-[[(5-phenyl-2-pyrimidinyl)carbonyl]amino]-2-quinolinyl]-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 801252-31-3 CAPLUS
CN 2-Pyrimidinecarboxamide, N-[2-[(3R)-3-[[(dimethylamino)carbonyl]methylamino]-1-pyrrolidinyl]-6-quinolinyl]-5-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 801252-34-6 CAPLUS
CN 2-Pyrimidinecarboxamide, N-[2-[methyl(1-methylethyl)amino]-6-quinolinyl]-5-phenyl- (CA INDEX NAME)



RN 801252-37-9 CAPLUS
CN 2-Pyrimidinecarboxamide, 5-(4-fluorophenyl)-N-[2-[(3R)-3-[methyl(2-methyl-1-oxopropyl)amino]-1-pyrrolidinyl]-6-quinolinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 801252-40-4 CAPLUS
CN 2-Pyrimidinecarboxamide, N-[2-[(3R)-3-(acetylmethylamino)-1-pyrrolidinyl]-6-quinolinyl]-5-(4-fluorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 801252-43-7 CAPLUS
CN 2-Pyrimidinecarboxamide, 5-(4-fluorophenyl)-N-[2-[methyl(tetrahydro-3-furanyl)amino]-6-quinolinyl]- (CA INDEX NAME)



RN 801252-46-0 CAPLUS
CN 2-Pyrimidinecarboxamide, 5-(3-fluorophenyl)-N-[2-[(3R)-3-[methyl(2-methyl-1-oxopropyl)amino]-1-pyrrolidinyl]-6-quinolinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    5.93     184.96

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -0.80      -0.80

STN INTERNATIONAL LOGOFF AT 14:06:36 ON 22 JUN 2008
```